IFN-γ–related mRNA profile predicts clinical response to PD-1 blockadeMark Ayers, Terrill K. McClanahan, Jared Lunceford et al.|Journal of Clinical Investigation|2017Cited by 3.9k
AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancerDavid S. Hong, A. Robert MacLeod, Razelle Kurzrock et al.|Science Translational Medicine|2015Cited by 438
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Patrick A. Ott, Sarina A. Piha‐Paul et al.|Journal of Thoracic Oncology|2019Cited by 437
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A. Yap, Marina Konopleva, Natalia Baran et al.|Nature Medicine|2023Cited by 372
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J. Reilley, David S. Hong, Patricia McCoon et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 286